ClinicalTrials.gg
CompletedNCT05027230Updated Sep 19, 2024

A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

A Phase 1/2 interventional study of STSP-0601 for Injection and STSP-0601 for Injection in Hemophilia, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Completed at 1 site in China. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies in Hemophilia A with a site in China — 28 open to participants now, 39 under way, 19 of them phase 3. Hemophilia A · China.

Enrollment
24th of 80
77 · median 54
Started
2021
with 10 others
Phase 1/2
5 of 93
2 open now
Registered
45th of 93
by date
Lead sponsor
4 of 93
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Among the 93 studies in Hemophilia A with a site in China, this one is the 24th largest by enrollment of the 80 interventional ones that give a count, is one of 11 that started in 2021, is one of 5 in phase 1/2, and was the 45th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

28 of the 93 studies in Hemophilia A with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Hemophilia A with a site in China, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors.

03

Conditions studied

  • Hemophilia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old ≤age≤65 years of age,male.
  • Hemophilia A or B patients with inhibitors.
  • Received hemostatic treatment with drug, or to undergo minor surgical or other invasive procedures (Only for phase 2. Minor surgical procedures: procedures without general anesthesia and the wounds are easy to observe).
  • Peak historical inhibitor titer ≥ 5 BU and a positive inhibitor test when enrolled.
  • Establish proper venous access.
  • Agree to use adequate to avoid pregnancy.
  • Provide signed .

Exclusion criteria

Exclusion Criteria:

  • Have any coagulation disorder other than hemophilia A or B.
  • Treat with prophylactic treatment of coagulation factor.
  • Treat with anticoagulant within 7d of the time of study drug administration.
  • Have a history of arterial and/or venous thromboembolic events.
  • Have \<100,000/mL,\<90g/L.
  • Severe liver or kidney disease.
  • Bleeding in the central nervous system or throat before screening.
  • Accept major operation or blood transfusion within 1 month of the time of screening.
  • positive with current of less than 200/μl.
  • Have a known allergy to Blood product.
  • Participate in other clinical research within 1 month of the time of study drug administration.
  • Treat with coagulant within 7d of the time of study drug administration.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Consecutive doses of low-dose of STSP-0601

    Drug: STSP-0601 for Injection

  • Experimental
    Consecutive doses of high-dose of STSP-0601

    Drug: STSP-0601 for Injection

Interventions

  • A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia

  • A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Time frame: From day 0 to up to day 8

  2. Proportion of successfully treated bleeding episodes

    Time frame: 24 hours after administration of study drug

Secondary outcomes

  1. Proportion of bleeding episodes with clinical relief of signs and symptoms

    Time frame: 4 hours、8 hours、24 hours after first administration of study drug

07

Study locations

1 site
  • Hospital of Hematology, Chinese Academy of Medical Sciences
    Tianjin, Tianjin 300020, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jul 2023, 21 months.

Of 20 phase 1/2 interventional studies under Hemophilia A, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 94. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2021
First posted
Aug 30, 2021
StartActual
Oct 12, 2021
Primary completionActual
Jul 15, 2023
CompletionActual
Jul 29, 2023
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05027230
Responsible party
Sponsor
First posted
Aug 30, 2021
Start date
Oct 12, 2021
Primary completion
Jul 15, 2023
Completion
Jul 29, 2023
Last update
Sep 19, 2024

Study contacts

Lei Zhang, Ph.D
principal investigator · Hospital of Hematology, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STSP-0601

Start the discussion